Patientric today announced it has entered into a commercialization agreement with Emergent BioSolutions for the marketing and distribution of its oral typhoid and cholera vaccines in the United Kingdom.
The agreement with Patientric will enable Emergent BioSolutions to immediately reintroduce supply of oral typhoid fever vaccine into the UK travel health market whilst preparing for the much-anticipated launch of its new single dose live cholera vaccine, expected in the fourth quarter of 2022.
“Patientric selected for commercialization of Emergent BioSolutions’travel health vaccines in the UK.“
Through the new partnership, GP practices, community pharmacies and specialist travel clinics will be able to access Emergent’s Travel Health vaccines via Patientric whist unlocking a range of added-value support resources for clinics provided by Patientric and its strategic partners.
Patientric Director Chris Scott added “We are delighted to have been chosen by Emergent BioSolutions as their exclusive marketing and distribution partner in the UK. Our experienced team has a long history building novel business models which have significantly disrupted healthcare markets, so we are excited to continue our journey to bring new vaccines to UK market which will improve access, awareness and advice for both healthcare professionals and patients alike”.